Press coverage about Calithera Biosciences (NASDAQ:CALA) has been trending positive this week, Accern reports. The research group identifies negative and positive media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Calithera Biosciences earned a news impact score of 0.26 on Accern’s scale. Accern also assigned news headlines about the biotechnology company an impact score of 46.5706924944545 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Here are some of the news headlines that may have impacted Accern Sentiment Analysis’s analysis:
- Calithera Biosciences Inc to Post Q1 2019 Earnings of ($0.49) Per Share, William Blair Forecasts (CALA) (americanbankingnews.com)
- Calithera Biosciences Inc (CALA) Receives Average Recommendation of “Hold” from Analysts (americanbankingnews.com)
- Does Calithera Biosciences Inc’s (NASDAQ:CALA) Latest Financial Perfomance Look Strong? (finance.yahoo.com)
- Calithera Biosciences (CALA) Posts Quarterly Earnings Results, Misses Expectations By $0.09 EPS (americanbankingnews.com)
- Calithera Biosciences, Inc. to Host Earnings Call (finance.yahoo.com)
Several research analysts recently weighed in on the stock. Citigroup raised shares of Calithera Biosciences from a “neutral” rating to a “buy” rating and lifted their price objective for the stock from $6.95 to $14.00 in a research note on Friday, February 16th. ValuEngine lowered shares of Calithera Biosciences from a “sell” rating to a “strong sell” rating in a research note on Saturday, February 3rd. BidaskClub lowered shares of Calithera Biosciences from a “sell” rating to a “strong sell” rating in a research note on Thursday, January 18th. Finally, Zacks Investment Research lowered shares of Calithera Biosciences from a “buy” rating to a “hold” rating in a research note on Tuesday, January 2nd. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average price target of $16.67.
Calithera Biosciences (NASDAQ:CALA) last released its quarterly earnings data on Thursday, March 8th. The biotechnology company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.09). Calithera Biosciences had a negative return on equity of 17.49% and a negative net margin of 107.21%. The firm had revenue of $7.24 million for the quarter, compared to the consensus estimate of $7.28 million. During the same period in the previous year, the business earned ($0.45) EPS. analysts predict that Calithera Biosciences will post -0.8 EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “Calithera Biosciences (CALA) Getting Positive News Coverage, Study Shows” was published by BBNS and is the property of of BBNS. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of U.S. & international copyright laws. The legal version of this piece of content can be viewed at https://baseballnewssource.com/2018/03/13/calithera-biosciences-cala-getting-positive-news-coverage-study-shows/2025141.html.
About Calithera Biosciences
Calithera Biosciences, Inc is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells.
Receive News & Ratings for Calithera Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.